Biomarkers in Breast Carcinoma

Richard S.P. Huang, et al., The Oncologist

This article reports the current landscape of biomarkers in breast cancer, focusing on patients using comprehensive genomic profiling and PD‐L1 immunohistochemistry in addition to the previous standard of care diagnostics for hormone receptor and human epidermal receptor 2 identification. The relationship between different immunotherapy biomarkers in patients with triple‐negative breast cancer is examined.



Dr. Don DizonDiscussions with Don S. Dizon

Don S. Dizon is the Director of Women's Cancers at Lifespan Cancer Institute, Founder of The Oncology Sexual Health First Responders Clinic at Lifespan Cancer Institute, and Director of Medical Oncology at Rhode Island Hospital. Dr. Dizon is a Professor of Medicine at the Warren Alpert Medical School of Brown University.

COVID-19 has changed the way patients experience cancer care. Don Dizon and Anne Marie Mercurio discuss the impact of the pandemic on patients and their families.
In this month's blog post, Don Dizon discusses cooperative groups, social media, and conducting clinical trials during the COVID-19 pandemic with Wendy Lawton from SWOG.
Don Dizon learns about Ginny Mason's experiences as a breast cancer survivor, patient advocate, and nonprofit leader in this month's blog post.